Tricida Inc

Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tricida, Inc. is a late-stage pharmaceutical company focused on the development and commercialization of its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD). Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. Metabolic acidosis has been associated with increased muscle wasting, loss of bone density and death.

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2022 financial results after the close of market on Monday, August 8, 2022. Tricida will host a webcast and conference call at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows:

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 8, 2022

Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022 Expects to Announce Top-Line Results Early in the Fourth Quarter of 2022

Tricida Announces Administrative Stop of the VALOR-CKD Trial

Tricida, Inc. (NASDAQ:TCDA ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Jackie Cossmon - Investor Relations Gerrit Klaerner - Founder, Chief Executive Officer and President Geoff Parker - Chief Operating Officer and Chief Financial Officer Conference Call Participants Phil Nadeau - Cowen & Company Operator Good day and thank you for standing by. Welcome to the Tricida First Quarter 2022 Financial Results Conference Call.

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q1 2022 Results - Earnings Call Transcript

Webcast Today at 4:30 pm Eastern Time Webcast Today at 4:30 pm Eastern Time

Tricida Announces First Quarter 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2022 financial results after the close of market on Tuesday, May 10, 2022. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its first quarter financial results and business progress. The call or webcast may be accessed as follows:

Tricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Tuesday, May 10, 2022

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) announced today that it will present at the 21st Annual Needham Virtual Healthcare Conference on Monday, April 11, 2022 at 10:30 am Pacific Time / 1:30 pm Eastern Time. Tricida will provide a company overview, business update and progress on its key initiatives.

Tricida to Present at the Needham Virtual Healthcare Conference

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q4 2021 Results - Earnings Call Transcript

Tricida Announces Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its fourth quarter and year-end 2021 financial results after the close of market on Tuesday, March 29, 2022. Tricida will host a conference call and webcast at

Tricida to Report Fourth Quarter Financial Results and Host Conference Call and Webcast on Tuesday, March 29, 2022

SOUTH SAN FRANCISCO, Calif., March 02, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today an update on the anticipated date for top-line data from the VALOR-CKD trial based on the ongoing events in Ukraine. Approximately fifteen percent (15%) of the patients randomized in VALOR-CKD are from Ukraine. Given the uncertainty around future participation of Ukrainian subjects in the trial and the potential challenges to collecting and monitoring data from Ukrainian sites, top-line data from the VALOR-CKD trial is now anticipated early in the fourth quarter of 2022, versus Tricida's previous guidance of the third quarter of 2022. The revised guidance is based on Tricida's evaluation of the current situation in Ukraine which is dynamic. Its estimates may change as events in Ukraine evolve. Tricida believes it will need this incremental time to deal with anticipated disruptions and/or delays in data collection. Tricida does not expect the utility of the data already collected from Ukrainian subjects to be affected. Based upon the latest review of its forecast, Tricida believes that its financial resources will extend for approximately six months following the anticipated announcement of top-line results from the VALOR-CKD trial.

Tricida Provides Update on Timing of Top-Line Data for the VALOR-CKD Trial Based on Conflict in Ukraine

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA), a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow chronic kidney disease (CKD) progression in patients with metabolic acidosis and CKD, announced today that it will participate in a Kidney Disease / Fibrosis panel discussion at the Cowen 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 11:10 am PT / 2:10 pm ET.

Tricida to Participate in Cowen 42nd Annual Health Care Conference

SAN DIEGO--(BUSINESS WIRE)--Toragen Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that Dr. Sandra Coufal, M.D. will join Toragen as its new CEO. Dr. Coufal brings over 30 years of experience to Toragen as a physician and serial entrepreneur working with multiple successful companies in medicine, chemistry, biotechnology, material sciences,

Toragen, Inc. Announces Appointment of Dr. Sandra Coufal, M.D. as CEO

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 7:30 am PT / 10:30 am ET. Gerrit Klaerner, Ph.D., Tricida's Founder, President and CEO, will provide a company overview, business update and progress on the company's key initiatives. The live presentation will be accessible on the Tricida website at IR.Tricida.com. An archive of the webcast will be available for 30 days following the presentation.

Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference and the H.C.

SOUTH SAN FRANCISCO, Calif., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 2022 at 10:30 am PT / 1:30 pm ET. Gerrit Klaerner, Ph.D., Tricida's Founder, President and CEO, will provide a company overview, business update and progress on the company's key initiatives.

Tricida to Present at the 40th Annual J.P. Morgan Healthcare Conference

Investors need to pay close attention to Tricida (TCDA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Tricida (TCDA) Stock We Don't?

The stock price of Tricida Inc (NASDAQ: TCDA) increased by over 20% during intraday trading today. This is why it happened.

Tricida (TCDA) Stock: Why The Price Jumped Today

The drugmaker announced a stock and warrant offering.

Why Tricida Stock Is Jumping Today

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q3 2021 Results - Earnings Call Transcript

Tricida Announces Third Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its third quarter 2021 financial results after the close of market on Monday, November 8, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its third quarter financial results and business progress. The webcast or call may be accessed as follows:

Tricida to Report Third Quarter Financial Results and Host Conference Call and Webcast on Monday, November 8, 2021

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference. Tricida will provide a company overview, business update and progress on the company's key initiatives.

Tricida to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Tricida, Inc. (TCDA) CEO Gerrit Klaerner on Q2 2021 Results - Earnings Call Transcript

SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its second quarter 2021 financial results after the close of market on Monday, August 9, 2021. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its second quarter financial results and business progress. The webcast or call may be accessed as follows:

Tricida to Report Second Quarter Financial Results and Host Conference Call and Webcast on Monday, August 9, 2021

SAN DIEGO & SAN FRANCISCO--(BUSINESS WIRE)---- $TCDA #ClassAction--Shareholder rights law firm Robbins LLP is investigating Tricida, Inc. (NASDAQ: TCDA) to determine whether certain Tricida officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. Tricida is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of non-absorbed therapies. Its lead drug candidate veverimer (TRC101) is intended to slow the pro

Shareholder Alert: Robbins LLP is Investigating Tricida, Inc. (TCDA) for Shareholders

SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will present at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 12:50 pm PT / 3:50 pm ET. Gerrit Klaerner, Tricida's Founder, President and Chief Executive Officer, will provide a company overview, business update and progress on the company's key initiatives.

News for Tricida Inc Stock (TCDA)